Cargando…
Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma
PURPOSE: We retrospectively analyzed the risk of recurrence and conditional Disease-Free Survival (cDFS) in 63 patients with complete remission during treatment with tirosin kinase inhibitor (TKI), alone or with local treatment in metastatic renal cell carcinoma. RESULTS: 37% patients achieve CR wit...
Autores principales: | Santini, Daniele, Santoni, Matteo, Conti, Alessandro, Procopio, Giuseppe, Verzoni, Elena, Galli, Luca, di Lorenzo, Giuseppe, De Giorgi, Ugo, De Lisi, Delia, Nicodemo, Maurizio, Maruzzo, Marco, Massari, Francesco, Buti, Sebastiano, Altobelli, Emanuela, Biasco, Elisa, Ricotta, Riccardo, Porta, Camillo, Vincenzi, Bruno, Papalia, Rocco, Marchetti, Paolo, Burattini, Luciano, Berardi, Rossana, Muto, Giovanni, Montironi, Rodolfo, Cascinu, Stefano, Tonini, Giuseppe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078103/ https://www.ncbi.nlm.nih.gov/pubmed/27027342 http://dx.doi.org/10.18632/oncotarget.8302 |
Ejemplares similares
-
Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysis
por: Santini, Daniele, et al.
Publicado: (2017) -
Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?
por: Santoni, Matteo, et al.
Publicado: (2015) -
The amount of DNA combined with TP53 mutations in liquid biopsy is associated with clinical outcome of renal cancer patients treated with immunotherapy and VEGFR-TKIs
por: Del Re, Marzia, et al.
Publicado: (2022) -
BONSAI-2 study: Nivolumab as therapeutic option after cabozantinib failure in metastatic collecting duct carcinoma patients
por: Buti, Sebastiano, et al.
Publicado: (2022) -
First-line targeted therapies in the treatment of metastatic colorectal cancer – role of cetuximab
por: Tonini, Giuseppe, et al.
Publicado: (2009)